FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events

XARELTO® Has the Broadest Indication Profile of Any New Oral Anticoagulant

Summary:

Janssen Pharmaceuticals, Inc. (Janssen) today announced the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment.

Date: 02 November 2012, 17:45 PM EDT
Source: Janssen Pharmaceuticals, Inc.
Show/Hide more...

Social Media Tools:


Click asset titles for downloads, embeds and more...

Photos

Janssen Pharmaceuticals, Inc. (Janssen) today announced the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment.
Photo#1
Janssen Pharmaceuticals, Inc. (Janssen) today announced the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment.
Photo#2

Subscribe via RSS

RSSAll Content
RSSConsumer
RSSEntertainment
RSSFinancial
RSSGovernment
RSSHealthcare
RSSRetail
RSSTechnology

Register

Journalists who register may create email subscriptions to search results and a cart of assets to download. Click here to login, register or edit profile.

What Our Users
Are Saying

"I like the way the DC is easy to navigate, easy to find stories, easy to find when they were filed so you know if they’re out of date, and easy to see an on-line version of the available video" -- Allan C Lee, Director of News and Current Affairs